Skip to main content
Top
Published in: Abdominal Radiology 6/2017

01-06-2017

Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure?

Authors: Shane A. Wells, Vincenzo K. Wong, Tyler A. Wittmann, Meghan G. Lubner, Sara L. Best, Timothy J. Ziemlewicz, J. Louis Hinshaw, Fred T Lee Jr., E. Jason Abel

Published in: Abdominal Radiology | Issue 6/2017

Login to get access

Abstract

Purpose

To determine if renal mass biopsy should be performed before or during the ablation procedure with emphasis on complications and rate of ablation for renal cell carcinomas (RCC), benign tumors, and small renal masses without a histologic diagnosis.

Methods

This HIPAA-compliant, single-center retrospective study was performed under a waiver of informed consent from the institutional review board. Two hundred eighty-four consecutive patients with a small renal mass (≤4.0 cm) treated with percutaneous thermal ablation between January 2001 and January 2015 were included. Two cohorts were identified based upon the timing of renal mass biopsy: separate session two weeks prior to ablation and same session obtained immediately preceding ablation. Clinical and pathologic data were collected including risk factors for non-diagnostic biopsy. Two-sided t test, χ 2 test or Fischer’s exact tests were used to evaluate differences between cohorts. Univariate and multivariate logistic regression models were constructed.

Results

A histologic diagnostic was achieved more frequently in the separate session cohort [210/213 (98.6%) vs. 60/71 (84.3%), p < 0.0001]. The rate of ablation of RCC was higher in the separate session group [201/213 (94.4%) vs. 46/61 (64.7%), p = 0.001]. The rate of ablation for benign tumors [14/71 (19.7%) vs. 6/213 (2.8%), p < 0.0001] and small renal masses without a histologic diagnosis [3/213 (1.4%) vs. 11/71 (15.5%), p < 0.0001] was higher in the same session cohort. There were no high-grade complications in either cohort.

Conclusion

Performing renal mass biopsy prior to the day of ablation is safe, increases the rate of histologic diagnosis, and reduces the rate of ablation for benign tumors and small renal masses without a histologic diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623CrossRefPubMed Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623CrossRefPubMed
2.
go back to reference Corcoran AT, Russo P, Lowrance WT, et al. (2013) A review of contemporary data on surgically resected renal masses–benign or malignant? Urology 81(4):707–713CrossRefPubMed Corcoran AT, Russo P, Lowrance WT, et al. (2013) A review of contemporary data on surgically resected renal masses–benign or malignant? Urology 81(4):707–713CrossRefPubMed
3.
go back to reference Marconi L, Dabestani S, Lam TB, et al. (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumor biopsy. Eur Urol 69(4):660–673CrossRefPubMed Marconi L, Dabestani S, Lam TB, et al. (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumor biopsy. Eur Urol 69(4):660–673CrossRefPubMed
4.
go back to reference Leveridge MJ, Finelli A, Kachura JR, et al. (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60(3):578–584CrossRefPubMed Leveridge MJ, Finelli A, Kachura JR, et al. (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60(3):578–584CrossRefPubMed
5.
go back to reference Shannon BA, Cohen RJ, de Bruto H, Davies RJ (2008) The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 180(4):1257–1261CrossRefPubMed Shannon BA, Cohen RJ, de Bruto H, Davies RJ (2008) The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 180(4):1257–1261CrossRefPubMed
6.
go back to reference Volpe A, Finelli A, Gill IS, et al. (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504CrossRefPubMed Volpe A, Finelli A, Gill IS, et al. (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504CrossRefPubMed
7.
go back to reference Campbell SC, Novick AC, Belldegrun A, et al. (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279CrossRefPubMed Campbell SC, Novick AC, Belldegrun A, et al. (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279CrossRefPubMed
8.
go back to reference Escudier B, Porta C, Schmidinger M, et al. (2014) Renal cell carcinoma: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):49–56CrossRef Escudier B, Porta C, Schmidinger M, et al. (2014) Renal cell carcinoma: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):49–56CrossRef
9.
go back to reference Ljungberg B, Bensalah K, Canfield S, et al. (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefPubMed Ljungberg B, Bensalah K, Canfield S, et al. (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefPubMed
10.
11.
go back to reference Srigley JR, Amin MB, Delahunt B, et al. (2010) Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. Arch Pathol Lab Med 134(4):e25–e30PubMed Srigley JR, Amin MB, Delahunt B, et al. (2010) Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. Arch Pathol Lab Med 134(4):e25–e30PubMed
12.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
13.
go back to reference Prince J, Bultman E, Hinshaw L, et al. (2015) Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol 193(6):1899–1904CrossRefPubMed Prince J, Bultman E, Hinshaw L, et al. (2015) Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol 193(6):1899–1904CrossRefPubMed
14.
go back to reference Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort 6336 patients and results ofa survey. Ann Surg 240(2):95–101CrossRef Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort 6336 patients and results ofa survey. Ann Surg 240(2):95–101CrossRef
15.
go back to reference Tsivian M, Rampersaud EN Jr, Laguna Mdel P, et al. (2014) Small renal mass biopsy—how, what and when: report from an international consensus panel. BJU Int 113(6):854–863CrossRefPubMed Tsivian M, Rampersaud EN Jr, Laguna Mdel P, et al. (2014) Small renal mass biopsy—how, what and when: report from an international consensus panel. BJU Int 113(6):854–863CrossRefPubMed
16.
go back to reference Rybicki FJ, Shu KM, Cibas ES, et al. (2003) Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 180(5):1281–1287CrossRefPubMed Rybicki FJ, Shu KM, Cibas ES, et al. (2003) Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 180(5):1281–1287CrossRefPubMed
17.
go back to reference Barwari K, Beemster PW, Hew MN, et al. (2011) Are there parameters that predict a nondiagnostic biopsy outcome taken during laparoscopic-assisted cryoablation of small renal tumors? J Endourol 25(9):1463–1468CrossRefPubMed Barwari K, Beemster PW, Hew MN, et al. (2011) Are there parameters that predict a nondiagnostic biopsy outcome taken during laparoscopic-assisted cryoablation of small renal tumors? J Endourol 25(9):1463–1468CrossRefPubMed
18.
go back to reference Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C (2004) Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol 171(5):1802–1805CrossRefPubMed Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C (2004) Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol 171(5):1802–1805CrossRefPubMed
19.
go back to reference Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS (2009) Accuracy of percutaneous core biopsy in management of small renal masses. Urology 73(3):586–591CrossRefPubMed Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS (2009) Accuracy of percutaneous core biopsy in management of small renal masses. Urology 73(3):586–591CrossRefPubMed
20.
go back to reference Menogue SR, O’Brien BA, Brown AL, Cohen RJ (2013) Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention. BJU Int 111(4):E146–E151CrossRefPubMed Menogue SR, O’Brien BA, Brown AL, Cohen RJ (2013) Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention. BJU Int 111(4):E146–E151CrossRefPubMed
21.
go back to reference Atwell TD, Schmit GD, Boorjian SA, et al. (2013) Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 200(2):461–466CrossRefPubMed Atwell TD, Schmit GD, Boorjian SA, et al. (2013) Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 200(2):461–466CrossRefPubMed
22.
go back to reference Best SL, Park SK, Youssef RF, et al. (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(4):1183–1189CrossRefPubMed Best SL, Park SK, Youssef RF, et al. (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(4):1183–1189CrossRefPubMed
23.
go back to reference Breen DJ, Bryant TJ, Abbas A, et al. (2013) Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int 112(6):758–765CrossRefPubMed Breen DJ, Bryant TJ, Abbas A, et al. (2013) Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int 112(6):758–765CrossRefPubMed
24.
go back to reference Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA (2010) Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 116(13):3135–3142CrossRefPubMed Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA (2010) Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 116(13):3135–3142CrossRefPubMed
25.
go back to reference Seyam RM, Bissada NK, Kattan SA, et al. (2008) Changing trends in presentation, diagnosis and management of renal angiomyolipomas: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology 72(5):1077–1082CrossRefPubMed Seyam RM, Bissada NK, Kattan SA, et al. (2008) Changing trends in presentation, diagnosis and management of renal angiomyolipomas: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology 72(5):1077–1082CrossRefPubMed
26.
go back to reference Cristescu M, Abel EJ, Wells SA, et al. (2016) Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Intervent Radiol 39(3):433–440CrossRefPubMed Cristescu M, Abel EJ, Wells SA, et al. (2016) Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Intervent Radiol 39(3):433–440CrossRefPubMed
27.
go back to reference Dechet CB, et al. (1999) Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol 162(1):40–42CrossRefPubMed Dechet CB, et al. (1999) Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol 162(1):40–42CrossRefPubMed
28.
go back to reference Lane BR, Babineau D, Kattan MW, et al. (2007) A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol 178(7):429–434CrossRefPubMed Lane BR, Babineau D, Kattan MW, et al. (2007) A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol 178(7):429–434CrossRefPubMed
29.
go back to reference Crispen PL, Viterbo R, Boorjian SA, et al. (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13):2844–2852CrossRefPubMedPubMedCentral Crispen PL, Viterbo R, Boorjian SA, et al. (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13):2844–2852CrossRefPubMedPubMedCentral
30.
go back to reference Giunchi F, Fiorentino M, Vagnoni V, et al. (2016) Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumors occuring in 11 patients. Pathology 48(1):41–46CrossRefPubMed Giunchi F, Fiorentino M, Vagnoni V, et al. (2016) Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumors occuring in 11 patients. Pathology 48(1):41–46CrossRefPubMed
31.
go back to reference Ginzburg S, Uzzo R, Al-Saleem T, et al. (2014) Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy. J Urol 191(2):296–300CrossRefPubMed Ginzburg S, Uzzo R, Al-Saleem T, et al. (2014) Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy. J Urol 191(2):296–300CrossRefPubMed
32.
go back to reference Richard PO, Jewett MA, Bhatt JR, et al. (2016) Active surveillance for renal neoplasms with oncocytic features is safe. J Urol 195(3):581–586CrossRefPubMed Richard PO, Jewett MA, Bhatt JR, et al. (2016) Active surveillance for renal neoplasms with oncocytic features is safe. J Urol 195(3):581–586CrossRefPubMed
33.
go back to reference Stewart SB, Thompson RH, Psutka SP, et al. (2014) Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 32(36):4059–4065CrossRefPubMedPubMedCentral Stewart SB, Thompson RH, Psutka SP, et al. (2014) Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 32(36):4059–4065CrossRefPubMedPubMedCentral
34.
go back to reference Chawla SN, Crispen PL, Hanlon AL, et al. (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431CrossRefPubMed Chawla SN, Crispen PL, Hanlon AL, et al. (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431CrossRefPubMed
Metadata
Title
Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure?
Authors
Shane A. Wells
Vincenzo K. Wong
Tyler A. Wittmann
Meghan G. Lubner
Sara L. Best
Timothy J. Ziemlewicz
J. Louis Hinshaw
Fred T Lee Jr.
E. Jason Abel
Publication date
01-06-2017
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-1037-8

Other articles of this Issue 6/2017

Abdominal Radiology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine